In vitro biodistribution studies on clinically approved FGFR inhibitors ponatinib, nintedanib, erlotinib and the investigational inhibitor KP2692

In vitro biodistribution studies on clinically approved FGFR inhibitors ponatinib, nintedanib, erlotinib and the investigational inhibitor KP2692

Binding towards human serum albumin (HSA) and α1-acid glycoprotein (AGP) of three approved fibroblast growth factor receptor (FGFR) inhibitors ponatinib (PON), nintedanib (NIN) and erdafitinib (ERD), as well as the experimental drug KP2692 was studied by means of spectrofluorometric and UV-visible s...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Dömötör Orsolya
Mathuber Marlene
Kowol Christian R.
Dokumentumtípus: Cikk
Megjelent: 2024
Sorozat:EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 192
Tárgyszavak:
Kémiai tudományok
doi:10.1016/j.ejps.2023.106651

mtmt:34415568
Online Access:http://publicatio.bibl.u-szeged.hu/29004
Leíró adatok
Tartalmi kivonat:Binding towards human serum albumin (HSA) and α1-acid glycoprotein (AGP) of three approved fibroblast growth factor receptor (FGFR) inhibitors ponatinib (PON), nintedanib (NIN) and erdafitinib (ERD), as well as the experimental drug KP2692 was studied by means of spectrofluorometric and UV-visible spectrophotometric methods. Additionally, proton dissociation processes, lipophilicity, and fluorescence properties of these four molecules were investigated in detail.
Terjedelem/Fizikai jellemzők:10
ISSN:0928-0987

Hasonló tételek